甘李药业拟回购注销24.13万股限制性股票，注册资本将减少24.13万元

Summary of Key Points Core Viewpoint - Ganli Pharmaceutical Co., Ltd. announced the repurchase and cancellation of a portion of restricted stock, notifying creditors about the implications of this action [1][2]. Repurchase and Cancellation Reasons - On May 30, 2025, Ganli Pharmaceutical's board and supervisory board approved the repurchase and cancellation of 241,300 shares of restricted stock that no longer meet the incentive conditions, as per the company's 2022 and 2024 restricted stock incentive plans [2]. - Following the repurchase, the company's registered capital will decrease from 601,065,290 yuan to 600,823,990 yuan, a reduction of 241,300 yuan [2]. Creditor Information - The repurchase and cancellation will lead to a reduction in the company's registered capital, necessitating notification to creditors as per the Company Law of the People's Republic of China [3]. - Creditors have 30 days from the notification date, or 45 days from the announcement date if not notified, to claim their debts or request guarantees [3]. - Required documentation for debt claims includes valid debt documents and identification, with specific requirements for both corporate and individual creditors [3].